Renal Sympathetic Denervation: A Comprehensive Review

• Published in: Current problems in cardiology Vol. 46; no. 3; p. 100598
• Main Authors: Akinseye, Oluwaseun A., Ralston, Willis F., Johnson, Karen C., Ketron, Lowell L., Womack, Catherine R., Ibebuogu, Uzoma N.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01-03-2021
• ISSN: 0146-2806; 1535-6280
• DOI: 10.1016/j.cpcardiol.2020.100598

In 2017, the American College of Cardiology and American Heart Association released its updated blood pressure guidelines, redefining hypertension to be any systolic blood pressure ≥130 mm Hg or diastolic blood pressure ≥80 mm Hg. Among United States adults, these new parameters increased the prevalence of hypertension from 72.2 million (31.9%) to 103.3 million (45.6%) adults and decreased the rate of medication-controlled hypertension from 53.4% to 39% with the prevalence of resistant hypertension ranging from 12% to 18%. Results of the pivotal SPRINT trial showed that more intensive blood pressure control in diabetic patients decreased both cardiovascular events and all-cause mortality. However, even with ideal goals in mind, compliance remains an issue due to multiple causes, and approximately half of study participants had stopped taking their antihypertensive drug within a year. Renal sympathetic denervation is a process in which catheter-based techniques are used to ablate specific portions of the renal artery nerves with the goal of decreasing sympathetic nerve activity and reducing blood pressure. Several studies using renal artery denervation have already shown benefit in patients with resistant hypertension, and now newer trials are beginning to focus on those with stage II hypertension as an additional potential treatment population. This review will seek to summarize the current evidence surrounding renal artery denervation and discuss some of its future trials, current issues, and potential roles both in hypertension and other comorbidities.